TetraLogic Pharmaceuticals Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Update on SHAPE Alopecia Areata Program
For the nine months, the company reported loss from operations of $32,047,050 against $23,993,854 a year ago. Net loss was $35,451,987 against $24,018,623 a year ago. Diluted loss per common share was $1.52 against $1.10 a year ago. Adjusted net loss was $27,000,166 or $1.16 per basic and diluted share against $20,556,362 or $0.92 per basic and diluted share a year ago.
On November 2, 2015, the company announced that it has an open U.S. Investigational New Drug application in support of a Phase 2 clinical trial of SHAPE in patients with alopecia areata. The Phase 2 trial will be conducted in approximately forty patients.